
Problem statement
Pricing teams want to build value-based pricing models grounded in real-world evidence (RWE), but connecting RWE data to defensible pricing scenarios is a slow, largely manual analytical exercise. Build a tool that turns real-world evidence into structured value-based pricing scenarios, helping pricing teams build faster, better-supported pricing strategies.
One-pager
ValueLens
REAL-WORLD EVIDENCE FOR VALUE-BASED PRICING
Prototype One-Pager | For Raj's review
01 WHAT THE PROTOTYPE IS ABOUT ValueLens |
ValueLens is a working prototype of a data-driven platform that turns real-world evidence (RWE) into a defensible price for a therapy in the US market. It connects patient-level evidence (cohorts, outcomes and costs) to the economic arguments payers demand: ICER, QALYs, budget impact and net monetary benefit, culminating in simulated price points and outcomes-based contracts.
02 KEY PROBLEM IT ADDRESSES TODAY · WITH VALUELENS |
7 integrated modules from data to contract | 14 outcomes-based contracts modelled in the prototype | Weeks to Minutes value dossiers from live cohorts |
TODAY Value story assembled manually from disconnected sources, spreadsheets and one-off analyses: slow, hard to defend, poorly linked to payer reimbursement. | WITH VALUELENS One evidence-backed workspace where pricing decisions are driven by real-world data rather than assumptions. |
03 KEY FEATURES FROM EVIDENCE TO PRICE |
01 Data Sources Ingest and profile real-world data feeds (claims, EHR, registry) with quality and readiness checks. | 02 Cohort Builder Define patient cohorts by indication, line of therapy and matching (PSM), with patient counts and match status. |
03 Outcomes Engine Compute ICER, QALYs gained, budget impact (BIM) and net monetary benefit (NMB) from cohort outcomes. | 04 Value Calculator Model the value story (comparator, effectiveness and cost deltas) behind the price. |
05 Pricing Simulator Simulate price points against willingness-to-pay thresholds and see ICER and NMB react instantly. | 06 Contracting Design outcomes-based agreements (OBAs) and track 14 contracts in market. |
07 Reports Export board-ready value dossiers for payer and internal review. | THE PAYER LANGUAGE ICER QALY BIM NMB Cohort outcomes to price and contract |
THE EVIDENCE-TO-PRICE FLOW
|
04 EXPECTED BUSINESS IMPACT |
Faster price submissions Value dossiers and ICER analyses that take weeks of analyst effort are generated in minutes from live cohorts. | Stronger payer negotiations Evidence-backed ICER, QALY and budget-impact views give teams a quantified value story at the negotiation table. | De-risked pricing decisions The pricing simulator lets leadership test price points against willingness-to-pay thresholds before committing. | New contracting capability Outcomes-based agreements become operational: 14 contracts modelled show refund/risk exposure transparently. |
Portfolio visibility Executives see cost-vs-QALY trends, ICER frontier and cohort performance across indications on one dashboard. |